Page 76 - 《中国药房》2024年23期

[ 9 ] SALHAB M，MIGDADY Y，DONAHUE M，et al. Immu‐ sis from China[J]. Front Pharmacol，2022，13：967182.
nohistochemical expression and prognostic value of PD- [19] U.S. Department of Health and Human Services National
L1 in extrapulmonary small cell carcinoma：a single insti‐ Institutes of Health National Cancer Institute. Common
tution experience[J]. J Immunother Cancer，2018，6（1）：42. terminology criteria for adverse events version 6.0，
[10] JIN Z X，WANG J P，SUN J J，et al. PD-1/PD-L1 based CTCAE[EB/OL].（2020-10-30）[2024-11-12]. https：//ctep.
immunochemotherapy versus chemotherapy alone for ad‐ cancer.gov/protocolDevelopment/electronic_applications/
vanced esophageal squamous cell carcinoma：a meta- ctc.htm#ctc_60.
analysis focus on PD-L1 expression level[J]. Cancer Rep， [20] GIULIANI J，BONETTI A. Cost-effectiveness of newer
2023，6（7）：e1794. regimens for the prophylaxis of chemotherapy-induced
[11] SHAH M A，KOJIMA T，HOCHHAUSER D，et al. Effi‐ nausea and vomiting：review of the literature and real-
cacy and safety of pembrolizumab for heavily pretreated world data[J]. Curr Opin Oncol，2020，32（4）：269-273.
patients with advanced，metastatic adenocarcinoma or [21] 陈秋平，邵明义，张容容，等. 信迪利单抗联合化疗方案
squamous cell carcinoma of the esophagus：the phase 2 一线治疗晚期、复发或转移性食管鳞状细胞癌的成本-
KEYNOTE-180 study[J]. JAMA Oncol，2019，5（4）： 效用分析[J]. 中国药房，2023，34（3）：345-349，360.
546-550. CHEN Q P，SHAO M Y，ZHANG R R，et al. Cost-utility
[12] LI J，CHEN Z D，BAI Y X，et al. First-line sugemalimab analysis of sintilimab combined with chemotherapy in
first-line treatment of advanced，recurrent or metastatic
with chemotherapy for advanced esophageal squamous
esophageal squamous cell carcinoma[J]. China Pharm，
cell carcinoma：a randomized phase 3 study[J]. Nat Med，
2023，34（3）：345-349，360.
2024，30（3）：740-748.
[22] WILKE H，MURO K，VAN CUTSEM E，et al. Ramuci‐
[13] XIE Q，WEN F，WEI Y Q，et al. Cost analysis of adjuvant
rumab plus paclitaxel versus placebo plus paclitaxel in pa‐
therapy with XELOX or FOLFOX4 for colon cancer[J].
tients with previously treated advanced gastric or gastro-
Colorectal Dis，2013，15（8）：958-962.
oesophageal junction adenocarcinoma （RAINBOW）：a
[14] 刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国
double-blind，randomised phase 3 trial[J]. Lancet Oncol，
市场出版社，2020：4-5，19，27-28.
2014，15（11）：1224-1235.
LIU G E. Guidelines for pharmacoeconomic evaluation in
[23] YANG F，FU Y，KUMAR A，et al. Cost-effectiveness
China 2020[M]. Beijing：China Market Press，2020：4-5，
analysis of camrelizumab in the second-line treatment for
19，27-28.
advanced or metastatic esophageal squamous cell carci‐
[15] XU L Z，CHEN M S，ANGELL B，et al. Establishing cost-
noma in China[J]. Ann Transl Med，2021，9（15）：1226.
effectiveness threshold in China：a community survey of
[24] ZHOU C C，WANG Z P，SUN Y P，et al. Sugemalimab
willingness to pay for a healthy life year[J]. BMJ Glob
versus placebo，in combination with platinum-based che‐
Health，2024，9（1）：e013070.
motherapy，as first-line treatment of metastatic non-small-
[16] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会
cell lung cancer （GEMSTONE-302）：interim and final
（CSCO）食管癌诊疗指南2023[M]. 北京：人民卫生出版
analyses of a double-blind，randomised，phase 3 clinical
社，2023：68-91.
trial[J]. Lancet Oncol，2022，23（2）：220-233.
Guidelines Working Committee of the Chinese Society of
[25] HUANG H Q，TAO R，HAO S G，et al. Sugemalimab
Clinical Oncology. Chinese Society of Clinical Oncology
monotherapy for patients with relapsed or refractory extra‐
（CSCO） esophageal cancer diagnosis and treatment nodal natural killer/T-cell lymphoma （GEMSTONE-
guidebook 2023[M]. Beijing：People’s Health Publishing 201）：results from a single-arm，multicenter，phase Ⅱ
House，2023：68-91. study[J]. J Clin Oncol，2023，41（16）：3032-3041.
[17] LATIMER N R. Survival analysis for economic evalua‐ [26] 胡善联. 中国医保药品价格谈判回顾和展望[J]. 卫生经
tions alongside clinical trials：extrapolation with patient- 济研究，2024，41（1）：9-13.
level data：inconsistencies，limitations，and a practical HU S L. Review and prospects of medical insurance price
guide[J]. Med Decis Making，2013，33（6）：743-754. negotiation in China[J]. Health Econ Res，2024，41（1）：
[18] SHEN J，DU Y，SHAO R，et al. First-line sintilimab plus 9-13.
chemotherapy in locally advanced or metastatic esopha‐ （收稿日期：2024-03-24 修回日期：2024-09-08）
geal squamous cell carcinoma：a cost-effectiveness analy‐ （编辑：胡晓霖）

· 2902 · China Pharmacy 2024 Vol. 35 No. 23 中国药房 2024年第35卷第23期